Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/23/2867588/0/en/OncoC4-Announces-FDA-Clearance-of-IND-Application-for-Novel-SIGLEC-10-Immune-Checkpoint-Inhibitor-ONC-841-for-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/04/02/2855906/0/en/OncoC4-Expands-Scientific-Advisory-Board-with-Appointment-of-Heather-A-Wakelee-MD-FASCO.html
https://www.globenewswire.com//news-release/2024/02/22/2833651/0/en/OncoC4-Announces-First-Patient-with-Advanced-Prostate-Cancer-Dosed-in-Phase-1-2-Trial-of-BioNTech-partnered-BNT316-ONC-392-Program.html
https://www.globenewswire.com//news-release/2024/01/04/2803951/0/en/OncoC4-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/09/28/2751158/0/en/OncoC4-Strengthens-Leadership-Team-with-the-Appointment-of-Abid-Ansari-as-Chief-Financial-Officer.html
https://investors.biontech.de/news-releases/news-release-details/biontech-and-oncoc4-present-positive-phase-12-data-antibody
https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-sign-deal-co-develop-oncoc4s-cancer-drug-2023-03-20/
https://www.globenewswire.com/news-release/2022/12/30/2581242/0/en/UPDATE-OncoC4-Announces-First-Patient-Dosed-in-PRESERVE-004-a-Phase-2-Clinical-Trial-of-ONC-392-in-Combination-with-KEYTRUDA-Pembrolizumab-in-Patients-with-Platinum-Resistant-Ovari.html